References
- Kaatz S, Ahmad D, Spyropoulos AC, the Subcommittee on Control of Anticoagulation, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–2126.
- Xu Y, Schulman S, Dowlatshahi D, et al. Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thromb Res. 2019;182(July):12–19.
- Rozjabek HM, Coleman CI, Ashton V, et al. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. J Med Econ. 2019;22(8):751–759.
- Stevanović J, Pompen M, Le HH, et al. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS One. 2014;9(8):e103974.
- de Jong LA, Groeneveld J, Stevanovic J, et al. Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLOS One. 2019;14(9):e0222658–17.
- Franco L, Becattini C, Vanni S, et al. Clinically relevant non-major bleeding with oral anticoagulants: Non-major may not be trivial. Blood Transfus. 2018;16(4):387–391.
- Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–962.
- van Ommen CH, Piersma-Wichers G, van Diermen DE, et al. Landelijke Standard Keten Antistolling 2.0 voor de eerste- en tweedelijns zorg. Kennis instituut van Medisch Specialisten 2014. https://www.nhg.org/sites/default/files/content/nhg_org/uploads/lska.pdf.
- Hakkaart-van Roijen L, van der Linden N, Bouwmans C, et al. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Zorginstituut Ned. 2016;1:1–73.
- Baeten SA, van Exel NJA, Dirks M, et al. Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc. 2010;8(1):21.
- Central Bureau voor Statistiek (CBS). StatLine - Jaarmutatie HICP; Nederland, eurozone en Europese Unie, 2015 = 100 [Internet] [cited 2020 Jan 31]. Available from: https://opendata.cbs.nl/statline/#/CBS/nl/dataset/83135NED/table?ts=1580124435578.
- Stichting Farmaceutische Kerngetallen. Pharmaceutisch Weekblad. Jaargang 154 Nr 37. Available from: https://www.sfk.nl/publicaties/PW/2019/anticoagulantia-doac-blijft-terrein-winnen-op-vka.
- Hylek EM, Hanna M, Al-Khalidi HR, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
- Pisano E, Gatsonis C, Boineau R, et al. Dabigatran versus warfarin in patients with atrial fibrillation. Heart Fail. 2005;361:225–237.
- Jakobsen M, Kolodziejczyk C, Klausen FE, et al. S. Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study. BMC Health Serv. Res. 2017;17(1):398.
- Ramagopalan SV, Samnaliev M, Weir S, et al. Costs of gastrointestinal bleeding events in atrial fibrillation: a UK clinical practice research datalink study. Future Cardiol. 2019;15(5):367–375.
- Nota SPFT, Strooker JA, Ring D. Differences in response rates between mail, e-mail, and telephone follow-up in hand surgery research. Hand. 2014;9(4):504–510.